FI953981A0 - 2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi - Google Patents

2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi

Info

Publication number
FI953981A0
FI953981A0 FI953981A FI953981A FI953981A0 FI 953981 A0 FI953981 A0 FI 953981A0 FI 953981 A FI953981 A FI 953981A FI 953981 A FI953981 A FI 953981A FI 953981 A0 FI953981 A0 FI 953981A0
Authority
FI
Finland
Prior art keywords
benzyl
preparation
guanine derivatives
polycyclic guanine
polycyclic
Prior art date
Application number
FI953981A
Other languages
English (en)
Swedish (sv)
Other versions
FI953981A (fi
Inventor
Deen Tulshian
Brian A Mckittrick
Yan Xia
Samuel Chackalamannil
Dinesh Gala
Donald J Dibenedetto
Max Kugelman
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI953981A0 publication Critical patent/FI953981A0/fi
Publication of FI953981A publication Critical patent/FI953981A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
FI953981A 1993-02-26 1995-08-24 2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi FI953981A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2354993A 1993-02-26 1993-02-26
US2459993A 1993-02-26 1993-02-26
PCT/US1994/001728 WO1994019351A1 (en) 1993-02-26 1994-02-24 2-benzyl-polycyclic guanine derivatives and process for preparing them

Publications (2)

Publication Number Publication Date
FI953981A0 true FI953981A0 (fi) 1995-08-24
FI953981A FI953981A (fi) 1995-08-24

Family

ID=26697306

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953981A FI953981A (fi) 1993-02-26 1995-08-24 2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi

Country Status (14)

Country Link
US (1) US5939419A (fi)
EP (1) EP0686157A1 (fi)
JP (1) JPH08507068A (fi)
KR (1) KR960701058A (fi)
CN (1) CN1118600A (fi)
AU (1) AU681875B2 (fi)
CA (1) CA2156918A1 (fi)
FI (1) FI953981A (fi)
HU (1) HUT72640A (fi)
IL (1) IL108754A0 (fi)
NZ (1) NZ262797A (fi)
SG (1) SG43809A1 (fi)
TW (1) TW270118B (fi)
WO (1) WO1994019351A1 (fi)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AR004752A1 (es) * 1995-11-28 1999-03-10 Schering Corp 2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6403799B1 (en) * 1999-10-21 2002-06-11 Agouron Pharmaceuticals, Inc. Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EP1790652A1 (en) * 2001-08-28 2007-05-30 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
CN1315835C (zh) * 2001-08-28 2007-05-16 先灵公司 多环鸟嘌呤磷酸二酯酶v抑制剂
ES2429132T3 (es) 2001-08-31 2013-11-13 The Rockefeller University Atividad de fosfodiesterasa y regulación de la señalización mediada por fosfodiesterasa 1-B en el cerebro
CN1585771A (zh) * 2001-11-09 2005-02-23 先灵公司 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
JP2007500714A (ja) * 2003-07-31 2007-01-18 シェーリング　コーポレイション 勃起不全を処置するのに有用なキサンチンホスホジエステラーゼ５インヒビターの代謝物およびそれらの誘導体
TW200526664A (en) * 2003-11-21 2005-08-16 Schering Corp Phosphodiesterase V inhibitor formulation
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
CA2611312C (en) 2005-06-06 2013-12-03 Intra-Cellular Therapies, Inc. Organic compounds
US20080194592A1 (en) * 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
AU2006327317B2 (en) 2005-12-23 2010-11-25 Astrazeneca Ab GABA-B receptor modulators
BRPI0620372A2 (pt) 2005-12-23 2011-11-08 Astrazeneca Ab composto, composição farmaceutica, e, uso de um composto
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AU2007256633B2 (en) * 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
ES2411604T3 (es) 2006-11-13 2013-07-05 Intra-Cellular Therapies, Inc. Compuestos orgánicos
EP2089034A4 (en) * 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
US7901872B2 (en) 2007-05-21 2011-03-08 Macronix International Co., Ltd. Exposure process and photomask set used therein
KR20100023040A (ko) * 2007-06-21 2010-03-03 쉐링 코포레이션 폴리사이클릭 구아닌 유도체 및 이의 용도
US8273751B2 (en) 2007-12-06 2012-09-25 Takeda Pharmaceutical Company Limited Organic compounds
EP2240028B1 (en) * 2007-12-06 2016-07-20 Intra-Cellular Therapies, Inc. Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical
WO2009144548A1 (en) * 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
WO2009152133A1 (en) 2008-06-10 2009-12-17 Abbott Laboratories Novel tricyclic compounds
JP5710492B2 (ja) 2008-12-06 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EA201170770A1 (ru) 2008-12-06 2012-02-28 Интра-Селлулар Терапиз, Инк. Органические соединения
KR20110096032A (ko) 2008-12-06 2011-08-26 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
KR20110103949A (ko) * 2008-12-06 2011-09-21 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP5710493B2 (ja) 2008-12-06 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
JP2012518685A (ja) 2009-02-25 2012-08-16 イントラ−セルラー・セラピーズ・インコーポレイテッド 眼障害のためのｐｄｅ１阻害剤
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
SG10201507362TA (en) 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors
US8785639B2 (en) 2009-12-01 2014-07-22 Abbvie Inc. Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof
SI2506716T1 (sl) 2009-12-01 2017-10-30 Abb Vie Inc. Nove triciklične spojine
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
JP2016518343A (ja) 2013-03-15 2016-06-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
US9849132B2 (en) 2014-01-08 2017-12-26 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
EP3725789B1 (en) 2014-09-17 2022-03-09 Intra-Cellular Therapies, Inc. 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns)
CA2969597C (en) 2014-12-06 2023-10-24 Intra-Cellular Therapies, Inc. 1h-pyrazolo[4,3-c][1,5]naphthyridin-4(5h)-one compounds and their use as pde2 inhibitors
WO2016090380A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
BR122022024925B1 (pt) 2015-10-16 2023-11-28 Abbvie Inc Composição farmacêutica de liberação prolongada compreendendo (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil) pirroli-dina-1-carboxamida
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
ES2906107T3 (es) 2016-09-12 2022-04-13 Intra Cellular Therapies Inc Usos novedosos
JP7111720B2 (ja) 2016-12-28 2022-08-02 ダート・ニューロサイエンス・エルエルシー Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物
JP7254078B2 (ja) 2017-11-27 2023-04-07 ダート・ニューロサイエンス・エルエルシー Ｐｄｅ１阻害剤としての置換フラノピリミジン化合物
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
CH643260A5 (fr) * 1980-05-02 1984-05-30 Nestle Sa 1-allyl-3-butyl-8-methylxanthine, procede de preparation et utilisation dans un medicament.
US4663446A (en) * 1983-06-27 1987-05-05 Trustees Of The Univ. Of Massachusetts N2 (phenyl substituted) deoxy guanosine containing compounds
DE3324115A1 (de) * 1983-07-05 1985-01-17 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3347290A1 (de) * 1983-12-28 1985-07-11 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3445299A1 (de) * 1984-12-12 1986-06-19 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE69033614T2 (de) * 1989-10-20 2001-04-19 Kyowa Hakko Kogyo Kk Kondensierte Purinderivate
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
DE4022314A1 (de) * 1990-07-13 1992-01-16 Boehringer Ingelheim Kg Verfahren zur herstellung von 2-chlor-1,7-dihydropurin-6-on und verfahren zu dessen reinigung
DE4035599A1 (de) * 1990-11-06 1992-05-07 Dresden Arzneimittel Neue 5-(phenoxyalkanoylamino)-uracile, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP3260037B2 (ja) * 1994-06-17 2002-02-25 松下電器産業株式会社 超音波ドプラ血流計

Also Published As

Publication number Publication date
AU681875B2 (en) 1997-09-11
WO1994019351A1 (en) 1994-09-01
NZ262797A (en) 1997-08-22
CA2156918A1 (en) 1994-09-01
HUT72640A (en) 1996-05-28
CN1118600A (zh) 1996-03-13
IL108754A0 (en) 1994-06-24
AU6268794A (en) 1994-09-14
US5939419A (en) 1999-08-17
EP0686157A1 (en) 1995-12-13
JPH08507068A (ja) 1996-07-30
SG43809A1 (en) 1997-11-14
TW270118B (fi) 1996-02-11
FI953981A (fi) 1995-08-24
HU9502464D0 (en) 1995-10-30
KR960701058A (ko) 1996-02-24

Similar Documents

Publication Publication Date Title
FI953981A0 (fi) 2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi
FI973426A0 (fi) Bentsopyraania sisältävät yhdisteet ja menetelmä niiden valmistamiseksi
FI941137A (fi) 2-debentsoyyli-2-asyylitaksolijohdannaisia ja menetelmiä niiden valmistamiseksi
FI961599A (fi) 1N-alkyyli-N-aryylipyrimidiiniamiineja ja niiden johdannaisia
PT92487A (pt) Processo para a preparacao de derivados de peptidos
ATE162248T1 (de) Kreppverfahren
BR9408463A (pt) Novos derivados de ginkgolide e processo para sua preparação
PT98638A (pt) Processo para a preparacao de derivados de borsolina
CY2005005I1 (el) Pyrrolidine derivatives
PT90748A (pt) Processo par a preparacao de 4-amino-3-carboxi-quinoleinas e - naftiridinas
PT89779A (pt) Processo para a preparacao de derivados da piperidina
FI944713A (fi) 4-difenyylimetyylipiperidiinijohdannaisia ja menetelmä niiden valmistamiseksi
PT89780A (pt) Processo para a preparacao de derivados da tetrahidroisoquinolina
FI940769A (fi) Menetelmä 2-aminoatsolijohdannaisten valmistamiseksi
PT89922A (pt) Processo para a preparacao de derivados da tiazolidenodiona
DE69402126D1 (de) Anthracenderivate
PT89545A (pt) Processo para a preparacao de derivados da isoquinolinona
EE03878B1 (et) 5-O-desosaminüül-6-O-metüülerütronoliid A derivaadid, nende valmistamismeetod ja kasutamine bioaktiivsete ühendite valmistamiseks
PT877738E (pt) Processo para a preparacao de derivados de fenil-imidazolidina
FI940775A0 (fi) alfa-fenyyli-isoseriinijohdannaisten valmistusmentelmä ja niiden käyttö
PT91027A (pt) Processo para a preparacao de derivados peptidicos
PT89775A (pt) Processo para a preparacao de derivados de isoquinolina
PT92539A (pt) Processo para a preparacao de derivados de anfotericina b
FI944842A (fi) Fluoratut 4-aminoandrostadienonijohdannaiset ja menetelmä niiden valmistamiseksi
PT99268A (pt) Processo para a preparacao de derivados da 8-cloroquinolona

Legal Events

Date Code Title Description
FD Application lapsed